Australia's most trusted
source of pharma news
Saturday, 13 September 2025
Posted 12 September 2025 AM
The way multiple myeloma is funded on the PBS could be overhauled, with the PBAC meeting with clinicians, Myeloma Australia, and the Department of Health, Disability and Ageing to review restrictions on treatments.
The PBAC has released the Outcome Statement for the Multiple Myeloma Stakeholder Meeting held in July, where PBS-listed therapies for multiple myeloma (MM) and relapsed or refractory multiple myeloma (RRMM) were discussed.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.